Jul 16, 2024, 16:22
Elisabetta Bonzano: Internal Mammary Lymphadenopathy in Patients Treated with Neoadjuvant Chemotherapy
Elisabetta Bonzano, Radiation Oncologist at IRCCS San Matteo Polyclinic Foundation, shared on X:
“Internal Mammary Lymphadenopathy Does Not Impact Oncologic Outcomes in Patients Treated with Neoadjuvant Chemotherapy: Results from the I-SPY2 Clinical Trial Annals of Surgical Oncology
With a median follow up of 3.72 years (range 0.4-10.2), there was no difference between IM+ versus IM- in
LRR (5.6% vs. 3.8%; p = 0.25),
DR (9.1% vs. 7.9%; p = 0.58),
or EFS (61.6% vs. 57.2%; p = 0.48).
This was true for patients with and without pCR.”
Read further.
Source: Elisabetta Bonzano/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19